Ying is China Commercial Editor with PharmAsia News. She has been working with international healthcare business intelligence since 2007, covering China and South East Asian countries including Singapore, Taiwan, Thailand, Vietnam, the Philippines, Malaysia and Indonesia. Her work covers health care reform, new drug development, M&A and financing, partnering, business strategies and outsourcing.
Prior to joining Informa, Ying was the China Bureau Editor of BioPharm Insight, a Financial Times Group product. She led the investigative coverage on the important situations taking place within the healthcare industry, delivering breaking news and insights on the biopharmaceutical industry in China and Southeast Asia.
Ying has covered academic and industry meetings in China and Asia where she has interviewed C-level executives and key opinion leaders. She has also worked as an international business development assistant at a China-listed pharmaceutical company.
Ying holds a Master's degree in Public Health from the University of Westminster in London, and a bachelor’s degree in biotechnology.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ying Huang
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.
WuXi Biologics is aiming high to become the world’s biggest biologics manufacturer within five years after seeing strong confidence from capital markets in its growth potential and a boost from its new biologics manufacturing facility. The Chinese company plans on more investment in early 2018 to prepare for an expected biologics surge in China, its chief executive tells Scrip.
Tougher regulatory scrutiny by India amid its massive reliance on such raw materials from China is anticipated, but the current Indian inspection action is just 'normal regulatory duties,' a Shanghai-based regulatory officer said.
In addition to its latest collaboration with Sangamo, Pfizer also teams with Arvinas on protein-degradation therapies. AstraZeneca sells off four mature products to ANI, while Summit enhances its antibiotic capabilities with Discuva buyout and out-licenses Latin American rights to ridinilazole.